Given that CXCR1/2 blockade has been shown to reduce inflammation and tissue damage in diabetic complications, targeting this pathway could offer new avenues to enhance Breg differentiation and stability in metabolic disorders (84). This evidence concerns the gene CXCR1 and Other metabolic disease.